人参皂苷Rg3对表达多耐药基因的晚期胃癌患者生存期的影响.docVIP

人参皂苷Rg3对表达多耐药基因的晚期胃癌患者生存期的影响 　　doi：10.3969/j.issn.1007-614x.2014.15.5 　　摘 要 目的：观察人参皂苷Rg3对表达胎盘型谷胱甘肽-S-转移酶π（Glutathione-s-transferase π，GST-π）、P-糖蛋白（P-glycoprotein，P-gP）、拓扑异构酶Ⅱ（Topoisomerase Ⅱ，Topo-Ⅱ）等多耐药基因的晚期胃癌患者生存期的影响。方法：利用免疫组织化学技术检测晚期胃癌组织中GST-π、P-gP、Topo-Ⅱ蛋白的表达情况，选取48例初治胃癌组织中≥2个耐药基因蛋白表达阳性患者纳入试验，随机分为治疗组（25人）和对照组（23人），治疗组给予人参皂苷Rg3+奥沙利铂+替吉奥方案为主的化疗，对照组给予奥沙利铂+替吉奥方案为主的化疗，比较两组间生存期的差别。结果：治疗组的中位生存时间（23.000±1.655）个月，对照组的中位生存时间（13.000±1.497）个月，两组间生存期比较差异有统计学意义（P0.01）。结论：人参皂苷Rg3能较明显地延长有多耐药基因表达的晚期胃癌患者生存期，可能具有逆转晚期胃癌铂类化疗药物耐药的能力。 　　关键词 胃癌 人参皂苷Rg3 化疗 耐药 　　Effect of ginsenoside Rg3 on the survival time of advanced gastric cancer patients with expressing multiple drug resistance genes 　　Wang Pei1，2，Chen Guorong1 　　Xinxiang Medical University（Xinxiang City，Henan）4530031 　　The Peoples Hospital of Linying County，Henan 4626002 　　Abstract Objective：To observe the effect of ginsenoside Rg3 on the lifetime of advanced gastric cancer patients with expressing multiple drug resistance genes，such as placenta type of glutathione-s-transferaseπ（GST-π），P-glycoprotein（P-gP），topoisomerase Ⅱ（Topo-Ⅱ） and so on.Methods：The expression of GST-π，P-gP，Topo-Ⅱ protein in the advanced gastric cancer tissue were detected by immunohistochemistry.48 cases with 2 or more than 2 expressing positive resistance gene proteins in the early gastric cancer tissue were selected.They were randomly divided into the treatment group（25 cases） and the control group（23 cases）.The treatment group were treated with ginsenoside Rg3，oxaliplatin and gimeraciland oteracil porassium chemotherapy.The control group were treated with oxaliplatin and gimeraciland oteracil porassium chemotherapy.The difference of the survival time between the two groups was compared.Results：The median survival time of the treatment group was 23.000±1.655 months.The median survival time of the control group was 13.000±1.497 months. The difference of the survival time between the two groups was statistically significant（P0.01）.Conclusion：Ginseno